Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distal fusion vertebra selection in neurofibromatosis type 1 scoliosis: integrating CT/MRI-detected atrophic changes reduces long-term mechanical complications.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2026
Same author

Nicotine promotes cardiac fibrosis by regulating miR-125b-5p maturation via HNRNPA2B1-mediated METTL14-dependent m⁶A methylation: therapeutic reversal by cinacalcet HCl.

Journal of translational medicine·2026
Same author

CT-based radiomics for predicting the treatment response to PD-1/PD-L1 inhibitors combined with chemotherapy in unresectable gastric cancer.

Insights into imaging·2026
Same author

Enantioselective Total Synthesis of (+)-Subincanadine F via Organo-SOMO Catalysis.

Organic letters·2026
Same author

Carbene-catalyzed [2+2] cycloaddition of chloroaldehydes and isatin-derived ketimines for enantioselective synthesis of spirocyclic β-lactams.

Chemical communications (Cambridge, England)·2026
Same author

Phylogenetic Relatedness Determines Heterospecific Pollen-Pistil Compatibility and Reproductive Outcome in the Apocarpous Species <i>Sagittaria trifolia</i> (Alismataceae).

Ecology and evolution·2026

Related Experiment Video

Updated: May 1, 2026

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

9.3K

Hepatic-targeted gene delivery using cationic mannan vehicle.

Gui-Xin Ruan1, Tian-Yuan Zhang, Li-Ming Li

  • 1Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University , Hangzhou 310058, P. R. China.

Molecular Pharmaceutics
|April 17, 2014
PubMed
Summary

Researchers developed a novel spermine-mannan (SM) nonviral vehicle for gene therapy targeting liver diseases. This optimized SM system shows high hepatic transfection and low toxicity, offering a promising new treatment strategy.

Keywords:
gene deliveryhepatic targetingmannose receptorspermine-mannan

More Related Videos

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

6.6K
Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
10:02

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

1.7K

Related Experiment Videos

Last Updated: May 1, 2026

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

9.3K
Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

6.6K
Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
10:02

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

1.7K

Area of Science:

  • Biomedical Engineering
  • Gene Therapy
  • Hepatology

Background:

  • Hepatic diseases pose a growing global health challenge with limited pharmacotherapy options.
  • Current gene therapy for liver conditions faces hurdles like poor liver retention and side effects.

Purpose of the Study:

  • To develop and optimize a novel nonviral gene delivery vehicle specifically targeted to the liver.
  • To evaluate the efficacy and safety of the developed vehicle for treating hepatic diseases.

Main Methods:

  • Cationization of mannan with spermine to create a spermine-mannan (SM) gene delivery system.
  • In vitro optimization of the SM vehicle for cytotoxicity and transfection efficiency.
  • Assessment of SM's hepatic targeting, gene retention, serum interference, and liver toxicity.

Main Results:

  • The spermine-mannan (SM) system demonstrated effective hepatic targeting and prolonged gene retention in the liver.
  • The optimized SM vehicle (N/P of 20) showed reduced interference from serum.
  • High hepatic transfection efficiency was achieved with minimal observed liver toxicity.

Conclusions:

  • The novel spermine-mannan (SM) nonviral vehicle is a promising candidate for targeted gene therapy in hepatic diseases.
  • The SM system overcomes key limitations of current gene delivery methods, offering improved efficacy and safety.